Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2017 | Retinal Disorders

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Authors: Masahiro Morimoto, Hidetaka Matsumoto, Kensuke Mimura, Hideo Akiyama

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2017

Abstract

Purpose

To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV).

Methods

In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of injections for 2 years. Polypoidal lesions were also evaluated before treatment and after the loading phase by indocyanine green angiography.

Results

BCVA significantly improved after the loading phase and was maintained in the maintenance phase. CMT and CCT significantly reduced after the loading phase and were maintained throughout the follow-up period. The number of injections averaged 7.72 in the first year and 4.67 in the second year. The average number of polypoidal lesions per patient was 2.43 before treatment. In 32 patients (55.2%), polypoidal lesions regressed completely after the loading phase; these patients also needed significantly fewer injections compared to other patients. CCT at baseline was positively correlated with the decreased amount of CCT after 2 years and negatively correlated with the number of injections for 2 years.

Conclusions

Treat-and-extend intravitreal therapy with aflibercept may be effective for improving BCVA and exudative change in eyes with PCV. The regression of polypoidal lesions after the loading phase and thicker choroid at baseline might lead to fewer total number of intravitreal injections of aflibercept.

Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA (1997) The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 115(4):478–485CrossRefPubMed

Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139. doi:10.1016/j.preteyeres.2016.04.002 CrossRefPubMed

Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144(1):15–22. doi:10.1016/j.ajo.2007.03.047 CrossRefPubMed

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431. doi:10.1056/NEJMoa054481 CrossRefPubMed

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444. doi:10.1056/NEJMoa062655 CrossRefPubMed

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148(1):43–58 e41. doi:10.1016/j.ajo.2009.01.024 CrossRefPubMed

Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L (2012) HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119(6):1175–1183. doi:10.1016/j.ophtha.2011.12.016 CrossRefPubMed

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046 CrossRefPubMed

Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143(4):679–680. doi:10.1016/j.ajo.2007.02.024 CrossRefPubMed

10.

Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD (2015) Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159(1):3–8 e1. doi:10.1016/j.ajo.2014.09.011 CrossRefPubMed

11.

Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S (2011) Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 95(11):1555–1559. doi:10.1136/bjophthalmol-2011-300285 CrossRefPubMed

12.

Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453–1464. doi:10.1097/IAE.0b013e31824f91e8 CrossRefPubMed

13.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H (2012) One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 154(1):117–124 e111. doi:10.1016/j.ajo.2011.12.019 CrossRefPubMed

14.

Mori R, Yuzawa M, Akaza E, Haruyama M (2013) Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity. Jpn J Ophthalmol 57(4):365–371. doi:10.1007/s10384-013-0245-9 CrossRefPubMed

15.

Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R (2015) INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: the Fujisan study. Retina 35(8):1569–1576. doi:10.1097/IAE.0000000000000526 CrossRefPubMed

16.

Ijiri S, Sugiyama K (2015) Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 253(3):351–357. doi:10.1007/s00417-014-2707-2 CrossRefPubMed

17.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2015) Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol 99(9):1284–1288. doi:10.1136/bjophthalmol-2014-306432 CrossRefPubMed

18.

Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T (2015) One-year results of intravitreal Aflibercept for Polypoidal choroidal vasculopathy. Ophthalmology 122(9):1866–1872. doi:10.1016/j.ophtha.2015.05.024 CrossRefPubMed

19.

Hosokawa M, Morizane Y, Hirano M, Kimura S, Kumase F, Shiode Y, Doi S, Toshima S, Hosogi M, Fujiwara A, Mitsuhashi T, Shiraga F (2016) One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. doi:10.1007/s10384-016-0492-7

20.

Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H (2017) Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255(2):311–316. doi:10.1007/s00417-016-3467-y CrossRefPubMed

21.

Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, Kim JW (2016) Intravitreal Aflibercept and Ranibizumab injections for Polypoidal choroidal vasculopathy. Am J Ophthalmol 165:1–6. doi:10.1016/j.ajo.2016.02.019 CrossRefPubMed

22.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2016) Subfoveal choroidal thickness during Aflibercept therapy for Neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123(3):617–624. doi:10.1016/j.ophtha.2015.10.039 CrossRefPubMed

23.

Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e7 CrossRefPubMed

24.

Stewart MW (2012) Aflibercept (VEGF trap-eye): the newest anti-VEGF drug. Br J Ophthalmol 96(9):1157–1158. doi:10.1136/bjophthalmol-2011-300654 CrossRefPubMedPubMedCentral

25.

Japanese study group of polypoidal choroidal vasculopathy (2005) Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese, with English abstract]. Nippon Gannka Gakkai Zasshi 109:417–427

26.

Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, Ehara K, Takayama M, Mimura K, Kishi S (2016) Treat-and-extend regimen with Aflibercept for retinal angiomatous proliferation. Retina 36(12):2282–2289. doi:10.1097/IAE.0000000000001104 CrossRefPubMed

27.

Yanai H (2015) Statcel- the useful add-in software forms on excel, 4th edn. OMS, Tokyo

28.

Patel KH, Chow CC, Rathod R, Mieler WF, Lim JI, Ulanski LJ 2nd, Leiderman YI, Arun V, Chau FY (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 27(5):663–667; quiz 668. doi:10.1038/eye.2013.31 CrossRef

29.

Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98(6):813–825. doi:10.1136/bjophthalmol-2013-304019 CrossRefPubMed

30.

Sato T, Kishi S, Matsumoto H, Mukai R (2013) Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 156(1):95–105 e101. doi:10.1016/j.ajo.2013.02.006 CrossRefPubMed

31.

Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151(4):594–603 e591. doi:10.1016/j.ajo.2010.10.030 CrossRefPubMed

32.

Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I (2015) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye (Lond) 29(3):342–349. doi:10.1038/eye.2014.258 CrossRef

33.

Mantel I (2015) Optimizing the anti-VEGF treatment strategy for Neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol 4(3):6. doi:10.1167/tvst.4.3.6 CrossRefPubMedPubMedCentral

34.

Cho JH, Ryoo NK, Cho KH, Park SJ, Park KH, Woo SJ (2016) Incidence rate of massive Submacular hemorrhage and its risk factors in Polypoidal choroidal vasculopathy. Am J Ophthalmol 169:79–88. doi:10.1016/j.ajo.2016.06.014 CrossRefPubMed

35.

Usui S, Ikuno Y, Akiba M, Maruko I, Sekiryu T, Nishida K, Iida T (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci 53(4):2300–2307. doi:10.1167/iovs.11-8383 CrossRefPubMed

Title: Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy
Authors: Masahiro Morimoto
Hidetaka Matsumoto
Kensuke Mimura
Hideo Akiyama
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3718-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2017

Intraocular silicone implant to treat chronic ocular hypotony: an in vivo trial

Post-hypoxic constriction of retinal arterioles is impaired during nitric oxide and cyclo-oxygenase inhibition and in diabetic patients without retinopathy

Incarceration of the inferior oblique muscle branch of the oculomotor nerve in patients with orbital floor trapdoor fracture

Baerveldt® glaucoma implant surgery with the double scleral flap technique to prevent Hoffman elbow exposure

Refining Coats’ disease by ultra-widefield imaging and optical coherence tomography angiography

Characteristics of retinal vessels in surgically closed macular hole: an optical coherence tomography angiography study